The Week in Review: March 2 – March 9, 2018

Friday, March 9, 2018 News Recap: Canada: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 – March 12 – 21, 2018. We are happy to announce that a 10-day roadtrip to northern Vancouver Island is just around the corner! We will be bringing hot-off-the-press posters, pamphlets, and audio-visual resources to community organizations and Friendship Centres, band health centres, and health clinics. See links to some of the resources we...

Lack of hep C treatment for N.S. inmates missed opportunity in disease control: advocates

Health-care practitioners say the lack of treatment options for provincial inmates with hepatitis C is creating inequities in health care and missing an opportunity to control the spread of the disease. Treatment for non-incarcerated Nova Scotians is publicly available. Dr. Lisa Barrett is an infectious disease doctor who sees inmates with HIV and hepatitis C at the Central Nova Scotia Correctional Facility in Dartmouth, N.S. She said when she sees

The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Nova Scotia Lists EPCLUSA™ on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection

Nova Scotia Also Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions MISSISSAUGA, ON, May 1, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective immediately, Nova Scotia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Nova Scotia: New drug will help with hepatitis C treatment

Nova Scotians will soon have access to a new drug to help treat hepatitis C. Nova Scotia’s Department of Health and Wellness announced Monday the province will provide public access to EPCLUSA tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C. With this drug, patients take one tablet daily for 12 weeks, provided they are adult patients without cirrhosis or with compensat

Hepatitis C rate increased in Nova Scotia, national rate decreased

Between 2005-2014, the rate of hepatitis C increased in Nova Scotia while the national rate decreased. According to provincial government data, the rate (per 100,000) was 26.7 (250 cases) in 2005 and flip-flopped over the years before reaching 34.4 (323 cases) in 2014. On the same dates, the Canadian rate went from 40.29 to 29.43, according to the Public Health Agency of Canada. “I don’t necessarily think that there’s more cases. I think that’s ther

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

Updated: HARVONI & SOVALDI now covered by BC PHARMACARE!!

HARVONI and SOVALDI ACCESS in CANADA, UPDATES as of March 26 (for original Press Release scroll to page bottom) British Columbia UPDATE on SOVALDI/HARVONI TREATMENT CRITERA and ACCESS as of March 26: BC PharmaCare Listing Criteria: http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/ledipasvir-sofosbuvir.html BC PharmaCare Information for Prescribers – Sofosbuvir-ledipasvir (Harvoni™) for the treatment of chronic hepatitis C infection g